Charles Sternberg, Assistant Editor03.31.21
SK Capital Partners LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has completed its previously announced acquisition of the Blow-Fill-Seal (BFS) Sterile Contract Development and Manufacturing business from Catalent Pharma Solutions. The business has been renamed Woodstock Sterile Solutions.
Woodstock is a BFS sterile contract development and manufacturing organization (CDMO) that operates out of a single site in Woodstock, Illinois, focusing on complex clinical to commercial stage formulation and manufacturing. The company supports a global, blue-chip customer base with a broad array of products that leverage its BFS sterile manufacturing capabilities and formulation competency in complex chemistries, including small molecule, biologics, macromolecules and potent compounds.
New CEO
Woodstock has also announced the appointment of Paul Josephs as the company’s chief executive officer, effective immediately. Josephs comes to Woodstock having most recently served as head of contract development & manufacturing and global business development at Mylan, a global generic and specialty pharmaceuticals company. Previously, Josephs held several leadership roles at DPT Laboratories.
Aaron Davenport, a managing director of SK Capital, stated, “We are excited to launch Woodstock Sterile Solutions as an independent company, building on its decades of experience in serving commercial and development customers. We are delighted that Paul Josephs is joining to lead the very capable Woodstock team. Paul is a CDMO industry veteran who brings sterile production experience and contemporary leadership skills to ensure an environment committed to operational excellence, customer delight, innovation and a partnership-driven approach for Woodstock’s customers, suppliers and employees.”
“I am truly honored and excited to lead an organization with the heritage and potential of Woodstock,” Josephs commented. “I look forward to partnering with SK Capital, the executive team and all Woodstock associates to leverage the Company’s unique sterile manufacturing capabilities, strong market position and exceptional talent to execute our growth strategy. The BFS and sterile manufacturing markets are significant growth areas in our industry and together we have a great opportunity to positively impact the lives of countless patients, domestically and abroad.”
Woodstock is a BFS sterile contract development and manufacturing organization (CDMO) that operates out of a single site in Woodstock, Illinois, focusing on complex clinical to commercial stage formulation and manufacturing. The company supports a global, blue-chip customer base with a broad array of products that leverage its BFS sterile manufacturing capabilities and formulation competency in complex chemistries, including small molecule, biologics, macromolecules and potent compounds.
New CEO
Woodstock has also announced the appointment of Paul Josephs as the company’s chief executive officer, effective immediately. Josephs comes to Woodstock having most recently served as head of contract development & manufacturing and global business development at Mylan, a global generic and specialty pharmaceuticals company. Previously, Josephs held several leadership roles at DPT Laboratories.
Aaron Davenport, a managing director of SK Capital, stated, “We are excited to launch Woodstock Sterile Solutions as an independent company, building on its decades of experience in serving commercial and development customers. We are delighted that Paul Josephs is joining to lead the very capable Woodstock team. Paul is a CDMO industry veteran who brings sterile production experience and contemporary leadership skills to ensure an environment committed to operational excellence, customer delight, innovation and a partnership-driven approach for Woodstock’s customers, suppliers and employees.”
“I am truly honored and excited to lead an organization with the heritage and potential of Woodstock,” Josephs commented. “I look forward to partnering with SK Capital, the executive team and all Woodstock associates to leverage the Company’s unique sterile manufacturing capabilities, strong market position and exceptional talent to execute our growth strategy. The BFS and sterile manufacturing markets are significant growth areas in our industry and together we have a great opportunity to positively impact the lives of countless patients, domestically and abroad.”
